Why Jazz Pharmaceuticals Shares Fell Out of Bed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharmaceutical company Jazz Pharmaceuticals dipped as much as 10% after the company reported its first-quarter results and following regulatory comments with regard to generic competition to its lead drug.

So what: For the quarter, Jazz reported an adjusted profit of $1.37 per share as product revenue nearly doubled to $194.6 million. As has been the case in the past, narcolepsy drug Xyrem led the charge with sales jumping 60% to $117.5 million. Comparatively, Wall Street had only expected EPS of $1.36 on $190.3 million in sales, yielding another earnings beat for shareholders. Looking forward, Jazz also boosted its EPS forecast to a range of $6.10-$6.30 from its previous guidance of $5.70-$5.90.

While this would normally send a company higher, comments from Jazz's regulatory filing that the Food and Drug Administration may approve a generic version of Xyrem being developed by Roxane Labs sent shareholders scurrying for the exits. With Xyrem comprising 60% of sales, that could be a big problem.

Now what: While the potential competition for Xyrem is certainly unwelcome news, an ongoing lawsuit between Jazz and Roxane appears even more likely now to involve a cash settlement for Roxane rather than Jazz allowing Roxane to bring the generic drug to market. Outside of what seem to largely overblown fears, Jazz continues to deliver incredible growth and profitability. Jazz is now valued at less than nine times the midpoint of this year's forecast with a revenue growth rate of 40% this year. If that wasn't enough, it also authorized a $200 million share repurchase program. If you are looking for significantly undervalued biopharmaceutical companies, I'd highly suggest digging deeper into Jazz Pharmaceuticals.

Craving more input? Start by adding Jazz Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

While you can certainly make huge gains in biopharmaceutical companies like Jazz, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Why Jazz Pharmaceuticals Shares Fell Out of Bed originally appeared on Fool.com.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.